肿瘤标志物在肺癌诊治中的应用进展  

Progress in the Application of Tumor Markers in the Diagnosis and Treatment of Lung Cancer

作　　者：王志波 WANG Zhibo(Department of Respiratory and Critical Care Medicine,Affi liated Hospital of Youjiang Medical University for Nationalities,Baise,Guangxi 533000)

机构地区：[1]右江民族医学院附属医院呼吸与危重症医学科,广西百色533000

出　　处：《科技与健康》2023年第7期17-20,共4页Technology and Health

摘　　要：肺癌因发病率、病死率较高,对人们的生命健康构成极大的威胁。肿瘤标志物表达量的异常往往发生在临床早期,由于其检测方法具有简单、快速、非侵入性和动态监控的特点,被广泛用于肺癌的治疗。目前临床上最常见的肺癌标志物有癌胚抗原、神经元特异性烯醇化酶、细胞角蛋白片段、前胃泌素释放肽及鳞状细胞癌抗原。现如今,单一的标志物难以应用于无症状人群或高危人群的肺癌筛查。但是,它对肺癌的鉴别诊断、疗效评价、复发或转移监测、预后判断具有重要的临床价值。阐述了肿瘤标志物在肺癌筛查中的应用情况,并展望了其研究及应用前景。Lung cancer poses a great threat to people’s life and health because of its high incidence rate and mortality.Abnormal expression levels of tumor markers often occur in the early stages of clinical practice,and their detection methods are widely used in the treatment of lung cancer due to their simple,fast,non-invasive,and dynamic monitoring characteristics.At present,the most common clinical lung cancer markers include carcinoembryonic antigen,neuron specifi c enolase,cell Keratin fragment,pre gastrin releasing peptide and squamous cell carcinoma antigen.Nowadays,it is diffi cult to apply a single marker to lung cancer screening in asymptomatic or high-risk groups.However,it has important clinical value in the diff erential diagnosis,effi cacy evaluation,recurrence or metastasis monitoring,and prognosis judgment of lung cancer.

关 键 词：肺癌 肿瘤标志物 临床诊断 预后 

分 类 号：R734.2[医药卫生—肿瘤]